B M Fendly

9.1k total citations · 3 hit papers
59 papers, 7.6k citations indexed

About

B M Fendly is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, B M Fendly has authored 59 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Radiology, Nuclear Medicine and Imaging, 26 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in B M Fendly's work include Monoclonal and Polyclonal Antibodies Research (34 papers), HER2/EGFR in Cancer Research (21 papers) and Glycosylation and Glycoproteins Research (12 papers). B M Fendly is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (34 papers), HER2/EGFR in Cancer Research (21 papers) and Glycosylation and Glycoproteins Research (12 papers). B M Fendly collaborates with scholars based in United States, France and United Kingdom. B M Fendly's co-authors include H. Michael Shepard, Gail D. Lewis Phillips, Axel Ullrich, Marcy Winget, Dennis J. Slamon, Leonard G. Presta, Robert S. Kerbel, Patricia Rockwell, Neil I. Goldstein and Janusz Rak and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

B M Fendly

58 papers receiving 7.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

1997 679 citations Janusz Rak, Mien‐Chie Hung et al. PubMed profile →
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

1994 560 citations Andrew Nuijens, B M Fendly et al. profile →
p185 ^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

1989 559 citations Robert M. Hudziak, Gail D. Lewis Phillips et al. Molecular and Cellular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B M Fendly United States	39	3.9k	3.5k	3.0k	1.5k	771	59	7.6k
H. Michael Shepard United States	39	4.8k 1.2×	4.5k 1.3×	3.8k 1.2×	2.0k 1.3×	508 0.7×	64	9.3k
William J. Gullick United Kingdom	60	6.0k 1.5×	5.1k 1.5×	3.0k 1.0×	871 0.6×	536 0.7×	154	10.3k
Gail D. Lewis Phillips United States	37	6.5k 1.6×	3.7k 1.1×	4.9k 1.6×	1.6k 1.0×	555 0.7×	80	10.4k
Zenon Steplewski United States	51	3.1k 0.8×	6.2k 1.8×	5.3k 1.8×	3.4k 2.2×	520 0.7×	172	11.0k
Christoph Wagener Germany	47	2.5k 0.6×	3.1k 0.9×	2.0k 0.6×	1.0k 0.7×	797 1.0×	154	6.5k
G. Riethmüller Germany	43	3.8k 1.0×	2.4k 0.7×	1.5k 0.5×	3.2k 2.1×	672 0.9×	137	8.9k
Silvana Canevari Italy	49	3.2k 0.8×	4.4k 1.2×	1.9k 0.6×	2.2k 1.5×	251 0.3×	227	8.7k
Dorothee Herlyn United States	46	3.3k 0.8×	3.9k 1.1×	3.8k 1.3×	3.2k 2.1×	529 0.7×	154	8.4k
Gerhard Moldenhauer Germany	52	2.7k 0.7×	3.4k 1.0×	1.8k 0.6×	2.9k 1.9×	314 0.4×	129	7.6k
Ermanno Gherardi United Kingdom	42	2.1k 0.5×	6.4k 1.8×	961 0.3×	1.1k 0.7×	421 0.5×	108	11.6k

Countries citing papers authored by B M Fendly

Since Specialization

Citations

This map shows the geographic impact of B M Fendly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B M Fendly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B M Fendly more than expected).

Fields of papers citing papers by B M Fendly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B M Fendly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B M Fendly. The network helps show where B M Fendly may publish in the future.

Co-authorship network of co-authors of B M Fendly

This figure shows the co-authorship network connecting the top 25 collaborators of B M Fendly. A scholar is included among the top collaborators of B M Fendly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B M Fendly. B M Fendly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desnoyers, Luc, Rebecca A. Simonette, Richard Vandlen, & B M Fendly. (2001). Novel Non-isotopic Method for the Localization of Receptors in Tissue Sections. Journal of Histochemistry & Cytochemistry. 49(12). 1509–1517. 5 indexed citations

Esserman, Laura J., Theresa Lopez, R. Montes, et al.. (1999). Vaccination with the extracellular domain of p185 neu prevents mammary tumor development in neu transgenic mice. Cancer Immunology Immunotherapy. 47(6). 337–342. 71 indexed citations

Rak, Janusz, Mien‐Chie Hung, Patricia Rockwell, et al.. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.. PubMed. 151(6). 1523–30. 679 indexed citations breakdown →

Phillips, Gail D. Lewis, et al.. (1996). Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.. PubMed. 56(6). 1457–65. 125 indexed citations

Hongo, Jo-Anne, M Mora-Worms, Catherine Lucas, & B M Fendly. (1995). Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β ₁. Hybridoma. 14(3). 253–260. 18 indexed citations

Bennett, Betsy D., Qiongnan Gu, B M Fendly, et al.. (1995). Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk.. Proceedings of the National Academy of Sciences. 92(6). 1866–1870. 91 indexed citations

Pietras, Richard J., et al.. (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.. PubMed. 9(7). 1829–38. 362 indexed citations

Phillips, Gail D. Lewis, Irene S. Figari, B M Fendly, et al.. (1993). Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunology Immunotherapy. 37(4). 255–263. 406 indexed citations

Kern, Jeffrey A., et al.. (1993). Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2 Antibody. American Journal of Respiratory Cell and Molecular Biology. 9(4). 448–454. 45 indexed citations

10.

Scott, Gary K., Robert Robles, John W. Park, et al.. (1993). A Truncated Intracellular HER2/neu Receptor Produced by Alternative RNA Processing Affects Growth of Human Carcinoma Cells. Molecular and Cellular Biology. 13(4). 2247–2257. 32 indexed citations

11.

Nakamura, Gerald, Randal A. Byrn, James P. Porter, et al.. (1992). Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse Isolates. AIDS Research and Human Retroviruses. 8(11). 1875–1885. 26 indexed citations

12.

Slamon, Dennis J., Stephen K. Anderson, Michael Shepard, et al.. (1992). Radiolabeled antibody targeting of the HER-2/neu oncoprotein.. PubMed. 52(7). 1916–23. 98 indexed citations

13.

Sarup, Jay, R. M. Johnson, K. L. King, et al.. (1991). Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.. PubMed. 1(2). 72–82. 142 indexed citations

14.

Teng, Michael N., et al.. (1991). Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.. Proceedings of the National Academy of Sciences. 88(9). 3535–3539. 91 indexed citations

15.

Fendly, B M, Claire E. Kotts, Doris Vetterlein, et al.. (1990). The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.. PubMed. 9(5). 449–55. 39 indexed citations

16.

Fendly, B M, et al.. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.. PubMed. 50(5). 1550–8. 348 indexed citations

17.

Natali, Pier Giorgio, Maria Rita Nicotra, A Bigotti, et al.. (1990). Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues. International Journal of Cancer. 45(3). 457–461. 205 indexed citations

18.

Hudziak, Robert M., Gail D. Lewis Phillips, Marcy Winget, et al.. (1989). p185 ^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor. Molecular and Cellular Biology. 9(3). 1165–1172. 559 indexed citations breakdown →

19.

Fendly, B M, Karen Toy, Abla A. Creasey, et al.. (1987). Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor. Hybridoma. 6(4). 359–370. 14 indexed citations

20.

Yang, Yue-tao, F. Carl Grumet, B M Fendly, Edgar G. Engleman, & John E. Shively. (1982). Protein A Binding Assay for the Identification of HLA Antigens on Peripheral Blood Lymphocytes by Monoclonal Antibodies: Application to HLA B27. Hybridoma. 1(3). 243–255. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact